Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

EW US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings

Edwards Lifesciences Corporation(EW US)

$107.15+1.351.28%Ext:$106.28-0.870.81%(After Hours · 00:36:21 UTC)
Ask AI
Doc SearchProfileEntity StructureEDINET FilingsFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings
Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

EW US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings

Edwards Lifesciences Corporation(EW US)

$107.15+1.351.28%Ext:$106.28-0.870.81%(After Hours · 00:36:21 UTC)
Ask AI
Doc SearchProfileEntity StructureEDINET FilingsFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings
EDINET Filings

Financials & Metrics

FinancialsChartingShort InterestEmployees
EDINET Filings

Financials & Metrics

FinancialsChartingShort InterestEmployees

Edwards Lifesciences Corporation — Company Profile

Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.

Sector
Materials
Industry
Paper & Forest Products
Exchange
UN
CEO
Bernard J. Zovighian
Headquarters
Irvine, CA, US
IPO Date
Mar 27, 2000
Employees
16,000
Website
www.edwards.com

Key Metrics

Price
$86.33
Market Cap
$49.71B
Revenue (TTM)
$1.65B
Net Income (TTM)
$380.70M
EPS (TTM)
0.66
P/E (TTM)
45.49
P/B (TTM)
4.81
Dividend Yield
0.00%
ROE (TTM)
3.69%
ROA (TTM)
2.86%
Operating Margin

Edwards Lifesciences Corporation — Company Profile

Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.

Sector
Materials
Industry
Paper & Forest Products
Exchange
UN
CEO
Bernard J. Zovighian
Headquarters
Irvine, CA, US
IPO Date
Mar 27, 2000
Employees
16,000
Website
www.edwards.com

Key Metrics

Price
$86.33
Market Cap
$49.71B
Revenue (TTM)
$1.65B
Net Income (TTM)
$380.70M
EPS (TTM)
0.66
P/E (TTM)
45.49
P/B (TTM)
4.81
Dividend Yield
0.00%
ROE (TTM)
3.69%
ROA (TTM)
2.86%
Operating Margin
31.22%
Beta
0.58

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Summary

Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.

Website
www.edwards.com
Location
Irvine, CA, US
Phone949 250 2500
Employees16,000
CEOBernard J. Zovighian
Sector
Materials
Industry
Paper & Forest Products
IPO DateMar 27, 2000

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.
How it makes money
A short diagram of the business model.

Latest Documents

SEC Filings(2.6K)

Expand
  • Form 4Lippis Daniel J.10 Nov
  • Form 144Lippis Daniel J.10 Nov
  • Form 4Zovighian Bernard J9 Nov
  • Form 4BOBO DONALD E JR9 Nov
  • Form 144Zovighian Bernard J9 Nov
  • Form 144BOBO DONALD E JR9 Nov
  • 10-QQ3ended 30 Sept 20264 Nov
  • 8-KResults of Operations and Financial Condition4 Nov
  • Form 4Lippis Daniel J.8 Oct
  • Form 4Markowitz Wayne14 Sep
  • Form 4Dahl Andrew M.14 Sep
  • Form 4Chopra Daveen11 Sep
  • Form 4Lippis Daniel J.11 Sep
  • Form 4Dahl Andrew M.31 Aug
  • Form 144Dahl Andrew M.31 Aug
  • Form 4Bruls Annette28 Aug
  • Form 144Bruls Annette28 Aug
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers28 Aug
  • Form 4Chopra Daveen26 Aug
  • Form 4Markowitz Wayne26 Aug

EDINET Filings(31)

Expand
  • IRExtraordinary Report21 Oct
  • IRExtraordinary Report21 Oct
  • IRSemi-Annual Report (2026.01.01-2026.12.31)30 Sep
  • IRExtraordinary Report22 Jun
  • IRExtraordinary Report22 Jun
  • 10-KAnnual Securities Report (2025.01.01-2025.12.31)29 Apr
  • IRExtraordinary Report29 Oct 2025
  • IRExtraordinary Report29 Oct 2025
  • IRCorrection Extraordinary Report29 Oct 2025
  • IRCorrection Extraordinary Report29 Oct 2025
  • IRSemi-Annual Report (2025.01.01-2025.12.31)29 Sep 2025
  • IRExtraordinary Report17 Jun 2025
  • IRExtraordinary Report17 Jun 2025
  • 10-KAnnual Securities Report (2024.01.01-2024.12.31)29 Apr 2025
  • IRExtraordinary Report15 Oct 2024
  • IRExtraordinary Report15 Oct 2024
  • IRSemi-Annual Report (2024.01.01-2024.12.31)29 Sep 2024
  • PRSSecurities registration statement13 Jun 2024
  • PRSSecurities registration statement13 Jun 2024
  • 10-KAnnual Securities Report (2023.01.01-2023.12.31)30 Apr 2024

News

  • Edwards Lifesciences Corporation $EW Stake Trimmed by Candriam S.C.A.9 Nov
  • Edwards Lifesciences Q3 Earnings Call Highlights7 Nov
  • Edwards Q3 Earnings & Revenues Surpass Estimates, Stock Climbs5 Nov
  • Edwards Lifesciences Corporation (EW) Q3 2026 Earnings Call Transcript4 Nov
  • Edwards Lifesciences Reports Third Quarter Results4 Nov
  • Buy, Sell, or Hold? Wednesday’s Top Upgrades and Downgrades: Adobe, Apple, Duolingo, Exxon Mobil, Fiserv, Fortinet, Gartner, Lockheed Martin, Skyworks Solutions, Visa and More4 Nov
  • Can Q3 Earnings Get Back On Track After Being Rattled By Big Tech's AI Prints?3 Nov
  • Edwards Lifesciences Corporation (EW) Discusses CLASP II TR and PROGRESS Trial Results in Tricuspid and TAVR Transcript3 Nov
  • Edwards Lifesciences Highlights PASCAL, TAVR Data Showing Patient Benefits2 Nov
  • CLASP II TR Trial Demonstrates Superior Clinical, Quality-of-Life Benefits With Edwards PASCAL System2 Nov
  • Progress Trial Demonstrates Edwards TAVR Is Superior to Clinical Surveillance for Moderate AS Patients With At-Risk Features2 Nov
  • Edwards' Q3 Earnings on the Horizon: What's in the Cards?30 Oct
  • Curious about Edwards Lifesciences (EW) Q3 Performance? Explore Wall Street Estimates for Key Metrics30 Oct
  • Edwards Lifesciences Continually Innovating Ahead Of Q3 Results, Cardio Portfolio Thrives29 Oct
  • Is This the Right Time to Hold EW Stock in Your Portfolio?22 Oct
  • FDA Approval of Edwards Lifesciences' PASCAL Precision System Opens New Treatment Pathway for Patients With Tricuspid Valve Disease21 Oct
  • Is EW Overvalued? DCF Says Worth $4021 Oct
  • Edwards Lifesciences Corporation $EW Stock: Birch Hill Investment Advisors LLC Trims Position18 Oct
  • First Citizens Bank & Trust Co. Makes New $792,000 Investment in Edwards Lifesciences Corporation $EW17 Oct
  • Edwards Lifesciences Corporation $EW Stock: Assenagon Asset Management S.A. Boosts Stake16 Oct

Mentions in Filings

  • … s to small manufacturers offering a limited selection of products. In addition, we face competition from providers of other medical therapies, such as pharmaceutical companies. Our primary competitors include <strong>Edwards Lifesciences Corporation</strong> and Medtronic. Currently, no competitor has a single-piece tissue TAVR commercially available or has publicly disclosed that a single-piece tissue TAVR is in development. Major shifts in industry market share …
    Anteris Technologies Global Corp.Edwards Lifesciences Corporation·ARS - Annual report to security holders·FY25·9 Nov
  • … if actual demand for our products is unaffected. We face intense competition in virtually all of our product lines, from, among others, Baxter, Ethicon (a Johnson & Johnson Company), Medtronic, Abbott Laboratories, <strong>Edwards Lifesciences</strong>, Becton, Dickinson and Company, Integra Life Sciences, LifeNet Health, Corcym, Anteris Technologies, Elutia (formerly Aziyo Biologics), Cook Medical, Gore & Associates, Terumo, LeMaitre Vascular, Maquet, Pfizer, Bi …
    ARTIVION, INC.Edwards Lifesciences Corporation·10-Q - Quarterly report Q3·Q3 26·6 Nov
  • … the head of engineering at NaviGate Cardiac Structures Inc., a company which developed tricuspid heart valve replacement and delivery system devices, and held roles at Medtronic Cardiac and Vascular Group (CVG) and <strong>Edwards Lifesciences</strong> Center for Advanced Cardiovascular Technology where he used his technical and leadership skills to drive early-stage medical device technologies from conception to commercialization. Dr. Alavi received his doctorat …
    enVVeno Medical CorpEdwards Lifesciences Corporation·DEF 14A - Definitive proxy statement·Q4 26·29 Oct
  • *Linda Park* joined our board of directors in November 2022. She is currently the Senior Vice President, Associate General Counsel and Corporate Secretary of <strong>Edwards Lifesciences Corporation</strong>, a global leader of patient-focused innovations for structural heart disease and critical care monitoring. Ms. Park is a member of the Senior Leadership Team and has been a member of the board of directors of the Edwards Lifesciences Foundation since January …
    BIOLARGO, INC.Edwards Lifesciences Corporation·DEF 14A - Definitive proxy statement·Q4 26·19 Oct
  • … s of data and analytics leadership experience across regulated life sciences environments, most recently as Head of Enterprise Data, AI & Advanced Analytics at Avidity Biosciences, and previously in senior roles at <strong>Edwards Lifesciences</strong> and Medtronic. | | ○ | Appointed Elena Ridloff, CFA, to the Board of Directors, effective August 6, 2026. Ms. Ridloff brings more than 20 years of leadership experience in finance, corporate development, investor r …
    IMMUNIC, INC.Edwards Lifesciences Corporation·EX-99.1 - 8-K - Results of Operations and Financial Condition·Q4 26·08:00AM
  • … | | | 9 | McKesson Corporation | 1,079.790 | 9,718.11 | | | | **Health Care Equipment - 17.06%** | | | | | 65 | Abbott Laboratories | 109.290 | 7,103.85 | | | 59 | DexCom, Inc. | 80.345 | 4,740.36 | | | 68 | <strong>Edwards Lifesciences Corporation</strong> | 105.810 | 7,195.08 | | | 7 | IDEXX Laboratories, Inc. | 702.590 | 4,918.13 | | | 16 | Intuitive Surgical, Inc. | 449.530 | 7,192.48 | | | 30 | Stryker Corporation | 318.790 | 9,563.70 | | | | **Health Care …
    Invesco Unit Trusts Series 2507Edwards Lifesciences Corporation·487 - Form 487 - VKUT 2507·Q4 26·12 Nov

Key Stats

Trading

Px/Chg 1D$86.34 / +1.39%
Avg Volume5.02M
Beta0.58
Mkt Cap49.71B
FD Mkt Cap52.24B

Float

Shrs Out/Float575.80M / 568.38M
Short Float0.02%
Days to Cover2.11
Stock Repurchased$521.80M

Current Valuation

EV47.97B
EV/EBITDA33.76
EV/Sales7.61
P/B4.81
P/S7.89
FCF Yield-0.04%
ROE3.69%
ROA2.86%
Current Ratio4.42

Estimates

P/E45.49
Est P/E0.00
Est EPS0.73
Est PEG0.00

Valuation

Metric5Yr AvgApr '23Apr '24May '25May '26Oct '26
PRICE-BASED RATIOS
Price / Earnings148.3335.2737.3910.75527.64130.58
Price / Sales17.909.9710.478.2530.6630.15
Price / Book Value6.229.247.894.494.654.81
Price / Free Cash Flow-376.0456.3083.30200.06136.13-2,356.00
ENTERPRISE VALUE METRICS
Enterprise Value48,426.053,602.052,059.342,612.545,887.947,968.1
Enterprise Value / Sales17.309.9610.397.8329.2429.10
Enterprise Value / EBITDA105.3427.3433.9224.73344.7695.96
Enterprise Value / EBIT141.3329.8937.4527.18507.61104.51

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue3.8%5,232.55,382.45,010.05,439.56,067.6
Gross Income4.3%4,006.64,215.23,972.74,322.04,740.7
EBITDA-6.7%1,890.11,960.41,534.91,723.11,429.5
EBIT-7.3%1,726.81,793.61,390.01,567.91,272.9
Net Income-8.1%1,503.11,521.91,402.44,174.61,073.5
EPS (Diluted)-6.4%2.382.442.306.971.83
BALANCE SHEET
Cash & ST Inv30.3%1,466.81,215.31,632.83,975.94,226.8
Total Assets12.7%8,502.68,292.59,363.213,055.313,697.2
Total Liabilities5.9%2,666.72,485.82,643.82,992.43,359.6
Total Shareholder Equity15.4%5,835.95,806.76,650.09,998.410,337.6
CASH FLOW
Net Operating Cash Flow-2%1,732.11,218.2895.8542.31,595.2
Cap Ex-5.8%-329.8-264.8-266.3-252.4-260.2
Free Cash Flow-1.2%1,402.3953.4629.5289.91,335.0

Enterprise Value Bridge

Millions USD13 Nov '26
Price (As of 13 Nov '26)106.86
Basic Shares575.80
Market Cap61,530.0
Diluted Shares577.60
Fully Diluted Shares Outstanding577.60
Fully Diluted Market Cap61,722.3
+Consolidated Debt704.5
−In-the-Money Convertible Debt—
+Capital Leases105.7
+Operating Leases—
−Cash & Equivalents-3,110.8
−Short-term Investments-1,533.9
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest100.4
+Pension Liabilities—
Enterprise Value59,224.1

Segment data

Revenue

by Products and services

  • Transcatheter Heart Valves74%
  • Surgical Heart Valve Therapy17%
  • Transcatheter Mitral And Tricuspid Therapies9%

Revenue

by Geography

  • United States58%
  • Europe25%
  • Rest Of World11%
  • Japan6%

Related companies

Amgen Inc

AMGN US

Gilead Sciences, Inc.

GILD US

Intuitive Surgical Inc

ISRG US

Moderna, Inc.

MRNA US

Argenx Se

ARGX US

Revolution Medicines, Inc.

RVMD US

Biogen Inc.

BIIB US

BioNTech SE

BNTX US

STERIS plc

STE US

Nordson Corp

NDSN US

Tyson Foods, Inc.

TSN US

Zimmer Biomet Holdings Inc.

ZBH US

31.22%
Beta
0.58

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Summary

Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.

Website
www.edwards.com
Location
Irvine, CA, US
Phone949 250 2500
Employees16,000
CEOBernard J. Zovighian
Sector
Materials
Industry
Paper & Forest Products
IPO DateMar 27, 2000

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.
How it makes money
A short diagram of the business model.

Latest Documents

SEC Filings(2.6K)

Expand
  • Form 4Lippis Daniel J.10 Nov
  • Form 144Lippis Daniel J.10 Nov
  • Form 4Zovighian Bernard J9 Nov
  • Form 4BOBO DONALD E JR9 Nov
  • Form 144Zovighian Bernard J9 Nov
  • Form 144BOBO DONALD E JR9 Nov
  • 10-QQ3ended 30 Sept 20264 Nov
  • 8-KResults of Operations and Financial Condition4 Nov
  • Form 4Lippis Daniel J.8 Oct
  • Form 4Markowitz Wayne14 Sep
  • Form 4Dahl Andrew M.14 Sep
  • Form 4Chopra Daveen11 Sep
  • Form 4Lippis Daniel J.11 Sep
  • Form 4Dahl Andrew M.31 Aug
  • Form 144Dahl Andrew M.31 Aug
  • Form 4Bruls Annette28 Aug
  • Form 144Bruls Annette28 Aug
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers28 Aug
  • Form 4Chopra Daveen26 Aug
  • Form 4Markowitz Wayne26 Aug

EDINET Filings(31)

Expand
  • IRExtraordinary Report21 Oct
  • IRExtraordinary Report21 Oct
  • IRSemi-Annual Report (2026.01.01-2026.12.31)30 Sep
  • IRExtraordinary Report22 Jun
  • IRExtraordinary Report22 Jun
  • 10-KAnnual Securities Report (2025.01.01-2025.12.31)29 Apr
  • IRExtraordinary Report29 Oct 2025
  • IRExtraordinary Report29 Oct 2025
  • IRCorrection Extraordinary Report29 Oct 2025
  • IRCorrection Extraordinary Report29 Oct 2025
  • IRSemi-Annual Report (2025.01.01-2025.12.31)29 Sep 2025
  • IRExtraordinary Report17 Jun 2025
  • IRExtraordinary Report17 Jun 2025
  • 10-KAnnual Securities Report (2024.01.01-2024.12.31)29 Apr 2025
  • IRExtraordinary Report15 Oct 2024
  • IRExtraordinary Report15 Oct 2024
  • IRSemi-Annual Report (2024.01.01-2024.12.31)29 Sep 2024
  • PRSSecurities registration statement13 Jun 2024
  • PRSSecurities registration statement13 Jun 2024
  • 10-KAnnual Securities Report (2023.01.01-2023.12.31)30 Apr 2024

News

  • Edwards Lifesciences Corporation $EW Stake Trimmed by Candriam S.C.A.9 Nov
  • Edwards Lifesciences Q3 Earnings Call Highlights7 Nov
  • Edwards Q3 Earnings & Revenues Surpass Estimates, Stock Climbs5 Nov
  • Edwards Lifesciences Corporation (EW) Q3 2026 Earnings Call Transcript4 Nov
  • Edwards Lifesciences Reports Third Quarter Results4 Nov
  • Buy, Sell, or Hold? Wednesday’s Top Upgrades and Downgrades: Adobe, Apple, Duolingo, Exxon Mobil, Fiserv, Fortinet, Gartner, Lockheed Martin, Skyworks Solutions, Visa and More4 Nov
  • Can Q3 Earnings Get Back On Track After Being Rattled By Big Tech's AI Prints?3 Nov
  • Edwards Lifesciences Corporation (EW) Discusses CLASP II TR and PROGRESS Trial Results in Tricuspid and TAVR Transcript3 Nov
  • Edwards Lifesciences Highlights PASCAL, TAVR Data Showing Patient Benefits2 Nov
  • CLASP II TR Trial Demonstrates Superior Clinical, Quality-of-Life Benefits With Edwards PASCAL System2 Nov
  • Progress Trial Demonstrates Edwards TAVR Is Superior to Clinical Surveillance for Moderate AS Patients With At-Risk Features2 Nov
  • Edwards' Q3 Earnings on the Horizon: What's in the Cards?30 Oct
  • Curious about Edwards Lifesciences (EW) Q3 Performance? Explore Wall Street Estimates for Key Metrics30 Oct
  • Edwards Lifesciences Continually Innovating Ahead Of Q3 Results, Cardio Portfolio Thrives29 Oct
  • Is This the Right Time to Hold EW Stock in Your Portfolio?22 Oct
  • FDA Approval of Edwards Lifesciences' PASCAL Precision System Opens New Treatment Pathway for Patients With Tricuspid Valve Disease21 Oct
  • Is EW Overvalued? DCF Says Worth $4021 Oct
  • Edwards Lifesciences Corporation $EW Stock: Birch Hill Investment Advisors LLC Trims Position18 Oct
  • First Citizens Bank & Trust Co. Makes New $792,000 Investment in Edwards Lifesciences Corporation $EW17 Oct
  • Edwards Lifesciences Corporation $EW Stock: Assenagon Asset Management S.A. Boosts Stake16 Oct

Mentions in Filings

  • … s to small manufacturers offering a limited selection of products. In addition, we face competition from providers of other medical therapies, such as pharmaceutical companies. Our primary competitors include <strong>Edwards Lifesciences Corporation</strong> and Medtronic. Currently, no competitor has a single-piece tissue TAVR commercially available or has publicly disclosed that a single-piece tissue TAVR is in development. Major shifts in industry market share …
    Anteris Technologies Global Corp.Edwards Lifesciences Corporation·ARS - Annual report to security holders·FY25·9 Nov
  • … if actual demand for our products is unaffected. We face intense competition in virtually all of our product lines, from, among others, Baxter, Ethicon (a Johnson & Johnson Company), Medtronic, Abbott Laboratories, <strong>Edwards Lifesciences</strong>, Becton, Dickinson and Company, Integra Life Sciences, LifeNet Health, Corcym, Anteris Technologies, Elutia (formerly Aziyo Biologics), Cook Medical, Gore & Associates, Terumo, LeMaitre Vascular, Maquet, Pfizer, Bi …
    ARTIVION, INC.Edwards Lifesciences Corporation·10-Q - Quarterly report Q3·Q3 26·6 Nov
  • … the head of engineering at NaviGate Cardiac Structures Inc., a company which developed tricuspid heart valve replacement and delivery system devices, and held roles at Medtronic Cardiac and Vascular Group (CVG) and <strong>Edwards Lifesciences</strong> Center for Advanced Cardiovascular Technology where he used his technical and leadership skills to drive early-stage medical device technologies from conception to commercialization. Dr. Alavi received his doctorat …
    enVVeno Medical CorpEdwards Lifesciences Corporation·DEF 14A - Definitive proxy statement·Q4 26·29 Oct
  • *Linda Park* joined our board of directors in November 2022. She is currently the Senior Vice President, Associate General Counsel and Corporate Secretary of <strong>Edwards Lifesciences Corporation</strong>, a global leader of patient-focused innovations for structural heart disease and critical care monitoring. Ms. Park is a member of the Senior Leadership Team and has been a member of the board of directors of the Edwards Lifesciences Foundation since January …
    BIOLARGO, INC.Edwards Lifesciences Corporation·DEF 14A - Definitive proxy statement·Q4 26·19 Oct
  • … s of data and analytics leadership experience across regulated life sciences environments, most recently as Head of Enterprise Data, AI & Advanced Analytics at Avidity Biosciences, and previously in senior roles at <strong>Edwards Lifesciences</strong> and Medtronic. | | ○ | Appointed Elena Ridloff, CFA, to the Board of Directors, effective August 6, 2026. Ms. Ridloff brings more than 20 years of leadership experience in finance, corporate development, investor r …
    IMMUNIC, INC.Edwards Lifesciences Corporation·EX-99.1 - 8-K - Results of Operations and Financial Condition·Q4 26·08:00AM
  • … | | | 9 | McKesson Corporation | 1,079.790 | 9,718.11 | | | | **Health Care Equipment - 17.06%** | | | | | 65 | Abbott Laboratories | 109.290 | 7,103.85 | | | 59 | DexCom, Inc. | 80.345 | 4,740.36 | | | 68 | <strong>Edwards Lifesciences Corporation</strong> | 105.810 | 7,195.08 | | | 7 | IDEXX Laboratories, Inc. | 702.590 | 4,918.13 | | | 16 | Intuitive Surgical, Inc. | 449.530 | 7,192.48 | | | 30 | Stryker Corporation | 318.790 | 9,563.70 | | | | **Health Care …
    Invesco Unit Trusts Series 2507Edwards Lifesciences Corporation·487 - Form 487 - VKUT 2507·Q4 26·12 Nov

Key Stats

Trading

Px/Chg 1D$86.34 / +1.39%
Avg Volume5.02M
Beta0.58
Mkt Cap49.71B
FD Mkt Cap52.24B

Float

Shrs Out/Float575.80M / 568.38M
Short Float0.02%
Days to Cover2.11
Stock Repurchased$521.80M

Current Valuation

EV47.97B
EV/EBITDA33.76
EV/Sales7.61
P/B4.81
P/S7.89
FCF Yield-0.04%
ROE3.69%
ROA2.86%
Current Ratio4.42

Estimates

P/E45.49
Est P/E0.00
Est EPS0.73
Est PEG0.00

Valuation

Metric5Yr AvgApr '23Apr '24May '25May '26Oct '26
PRICE-BASED RATIOS
Price / Earnings148.3335.2737.3910.75527.64130.58
Price / Sales17.909.9710.478.2530.6630.15
Price / Book Value6.229.247.894.494.654.81
Price / Free Cash Flow-376.0456.3083.30200.06136.13-2,356.00
ENTERPRISE VALUE METRICS
Enterprise Value48,426.053,602.052,059.342,612.545,887.947,968.1
Enterprise Value / Sales17.309.9610.397.8329.2429.10
Enterprise Value / EBITDA105.3427.3433.9224.73344.7695.96
Enterprise Value / EBIT141.3329.8937.4527.18507.61104.51

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue3.8%5,232.55,382.45,010.05,439.56,067.6
Gross Income4.3%4,006.64,215.23,972.74,322.04,740.7
EBITDA-6.7%1,890.11,960.41,534.91,723.11,429.5
EBIT-7.3%1,726.81,793.61,390.01,567.91,272.9
Net Income-8.1%1,503.11,521.91,402.44,174.61,073.5
EPS (Diluted)-6.4%2.382.442.306.971.83
BALANCE SHEET
Cash & ST Inv30.3%1,466.81,215.31,632.83,975.94,226.8
Total Assets12.7%8,502.68,292.59,363.213,055.313,697.2
Total Liabilities5.9%2,666.72,485.82,643.82,992.43,359.6
Total Shareholder Equity15.4%5,835.95,806.76,650.09,998.410,337.6
CASH FLOW
Net Operating Cash Flow-2%1,732.11,218.2895.8542.31,595.2
Cap Ex-5.8%-329.8-264.8-266.3-252.4-260.2
Free Cash Flow-1.2%1,402.3953.4629.5289.91,335.0

Enterprise Value Bridge

Millions USD13 Nov '26
Price (As of 13 Nov '26)106.86
Basic Shares575.80
Market Cap61,530.0
Diluted Shares577.60
Fully Diluted Shares Outstanding577.60
Fully Diluted Market Cap61,722.3
+Consolidated Debt704.5
−In-the-Money Convertible Debt—
+Capital Leases105.7
+Operating Leases—
−Cash & Equivalents-3,110.8
−Short-term Investments-1,533.9
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest100.4
+Pension Liabilities—
Enterprise Value59,224.1

Segment data

Revenue

by Products and services

  • Transcatheter Heart Valves74%
  • Surgical Heart Valve Therapy17%
  • Transcatheter Mitral And Tricuspid Therapies9%

Revenue

by Geography

  • United States58%
  • Europe25%
  • Rest Of World11%
  • Japan6%

Related companies

Amgen Inc

AMGN US

Gilead Sciences, Inc.

GILD US

Intuitive Surgical Inc

ISRG US

Moderna, Inc.

MRNA US

Argenx Se

ARGX US

Revolution Medicines, Inc.

RVMD US

Biogen Inc.

BIIB US

BioNTech SE

BNTX US

STERIS plc

STE US

Nordson Corp

NDSN US

Tyson Foods, Inc.

TSN US

Zimmer Biomet Holdings Inc.

ZBH US